Population-Based Models Increase Lung Cancer Screening Coverage

Optimizing Early Detection in High-Risk Lung Cancer Populations

Lung cancer remains the primary cause of cancer-related mortality globally, accounting for nearly half of the total decline in cancer deaths in recent years due to improved treatment and earlier detection [1, 2]. While the overall cancer death rate has dropped by 33% since 1991, the rising incidence of various malignancies in women and younger adults continues to challenge clinical progress [3, 4]. Annual screening with low-dose computed tomography (LDCT) is established as an effective intervention to reduce mortality among high-risk individuals, specifically those with a significant smoking history [5, 6]. Despite these clear clinical benefits, implementing effective screening at scale is hindered by low participation rates and significant disparities in access among underserved populations [7, 8]. A new analysis now evaluates which specific recruitment frameworks most effectively bridge the gap between clinical guidelines and real-world screening uptake.

A Systematic Evaluation of Recruitment Frameworks

Identifying the optimal pathway for patient entry into screening programs is essential for reducing the population-level burden of thoracic malignancies. The researchers conducted a systematic review to evaluate the most effective methods for identifying, reaching, and inviting at-risk populations to low-dose computed tomography (LDCT) screening. This nested systematic review (a secondary analysis of studies identified within a broader review to answer a specific clinical question) involved an extensive search of seven major medical databases: Medline, Embase, CINAHL, Scopus, Cochrane CENTRAL, Clinicaltrial.gov, and the WHO register. The search parameters encompassed studies published over a 23-year period, from January 2000 to March 2023. From an initial pool of 6,075 references, the final analysis included 79 studies describing 56 distinct lung cancer screening programs, providing a comprehensive overview of global recruitment frameworks and their clinical implementation.

Population-Based Strategies Yield Superior Coverage

The method of recruitment significantly dictates the reach of the intervention within the target demographic, with systematic approaches far outperforming opportunistic ones. The researchers found that population-based lung cancer screening programs achieved the highest test coverage, with rates ranging from 35% to 40%. These population-based models, which utilize systematic efforts to identify and invite all eligible individuals within a specific geographic region or health system, proved more effective at covering individuals at high risk compared to opportunistic strategies. By proactively identifying candidates through centralized registries or health records rather than waiting for patient or provider initiation, these programs ensure a more comprehensive capture of the eligible population. For the clinician, this suggests that institutional-level identification is a more reliable driver of screening than individual clinical encounters alone.

In contrast, models that rely on individual initiative or clinician triggers showed markedly lower penetration. Screening coverage in the 'volunteers' pattern, also known as self-referral, was only 4.8%, suggesting that relying on patient awareness alone misses the vast majority of the at-risk population. Similarly, screening coverage in the referral-based pattern was 6.7%, indicating that even when the healthcare system is involved through primary care or specialist referrals, the reach remains limited. These findings highlight a substantial gap in coverage between systematic, population-level invitations and traditional referral-based or opportunistic pathways, emphasizing that population-based programs were more effective at covering individuals at high risk.

The Paradox of Participation and Risk Assessment

A distinct discrepancy exists between the identification of high-risk individuals and their actual engagement with the screening process. In targeted programs, which focus on specific high-risk groups through focused outreach, the findings showed that participation rates ranged from 8.4% to 55.9%. Notably, these targeted programs maintained high risk assessment rates (the systematic process of evaluating whether a patient meets specific smoking history and age criteria for screening) even when actual participation remained low. This suggests that while clinicians and healthcare systems are successfully identifying eligible patients, a significant barrier remains in transitioning those patients from the point of identified risk to the actual completion of a low-dose computed tomography scan. This gap represents a critical point of clinical attrition where eligible patients are lost to follow-up despite being correctly identified as high-risk.

In contrast, participation rates in referral-based programs were highly variable, ranging from 30.9% to 92.5%. This wide range often reflects the strength of the existing patient-provider relationship and the intensity of the referral intervention, where a direct recommendation from a known physician can significantly drive patient compliance. However, the study identified a critical inverse relationship in recruitment efficacy: strategies successful in reaching the broad target population, thereby achieving high coverage, often resulted in low individual participation rates. Conversely, programs that achieved high participation rates among those invited often failed to cover a significant portion of the broader at-risk population. For the practicing clinician, this indicates that broad-reach strategies may lack the personal engagement necessary for patient follow-through, while high-touch referral models, though effective for the individual, may be too limited in scope to address the population-level burden of lung cancer.

Addressing Disparities and Improving Patient Retention

Tailored outreach remains the most effective tool for engaging marginalized communities and reducing health inequities. The systematic review highlighted significant variability in how effectively different programs engage these groups. Among underserved populations, participation rates ranged from 31% to 92%, a spread that underscores the impact of tailored outreach. The researchers found that participation in these underserved groups depended heavily on the specific interventions implemented to reach and retain them throughout the screening process. These interventions often included culturally specific communication, the removal of logistical barriers such as transportation, and intensive patient navigation (a support process where a dedicated staff member guides the patient through the complex healthcare system to ensure timely diagnosis and treatment). Despite these targeted efforts in specific subgroups, a sobering reality remains for clinicians: no screening program reached high overall test coverage across the entire eligible population. This suggests that even the most successful models currently in operation leave a substantial portion of the at-risk population without access to necessary preventative care.

To address these systemic gaps, the study identifies a critical need for interventions designed to retain eligible participants throughout the entire screening process, from the initial risk assessment to the completion of the low-dose computed tomography scan and subsequent follow-up. Because the screening pathway involves multiple steps where patients may disengage, the authors suggest that a fragmented approach is insufficient. Instead, a joint approach from the provider level to the patient level is recommended to increase lung cancer screening participation. For the practicing physician, this means that improving screening rates requires more than just a one-time referral; it necessitates a coordinated effort that combines clinical advocacy at the point of care with robust institutional support systems to ensure patients remain engaged with the protocol over the long term.

References

1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA A Cancer Journal for Clinicians. 2021. doi:10.3322/caac.21654

2. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet‐Tieulent J, Jemal A. Global cancer statistics, 2012. CA A Cancer Journal for Clinicians. 2015. doi:10.3322/caac.21262

3. Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA A Cancer Journal for Clinicians. 2023. doi:10.3322/caac.21763

4. Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A. Cancer statistics, 2025. CA A Cancer Journal for Clinicians. 2025. doi:10.3322/caac.21871

5. Huang K, Wang S, Lu W, Chang Y, Su J, Lu Y. Effects of low-dose computed tomography on lung cancer screening: a systematic review, meta-analysis, and trial sequential analysis.. BMC pulmonary medicine. 2019. doi:10.1186/s12890-019-0883-x

6. Wender RC, Fontham ETH, Barrera E, et al. American Cancer Society lung cancer screening guidelines. CA A Cancer Journal for Clinicians. 2013. doi:10.3322/caac.21172

7. Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA A Cancer Journal for Clinicians. 2024. doi:10.3322/caac.21820

8. Ali A, Pirie K, Hughes C, et al. Protocol for a hybrid systematic review of the barriers and facilitators to implementing lung cancer screening in community settings.. HRB Open Research. 2025. doi:10.12688/hrbopenres.13931.1